Ablynx (OTCMKTS:ABLYF) and Outlook Therapeutics (NASDAQ:OTLK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Earnings and Valuation

This table compares Ablynx and Outlook Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ablynx $62.73 million 0.00 -$122.67 million N/A N/A
Outlook Therapeutics $3.09 million 16.44 -$30.09 million ($10.80) -0.18

Outlook Therapeutics has lower revenue, but higher earnings than Ablynx.

Profitability

This table compares Ablynx and Outlook Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ablynx N/A N/A N/A
Outlook Therapeutics -1,250.20% N/A -143.81%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Ablynx and Outlook Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ablynx 0 0 0 0 N/A
Outlook Therapeutics 0 0 3 0 3.00

Outlook Therapeutics has a consensus price target of $9.33, suggesting a potential upside of 378.63%.

Risk and Volatility

Ablynx has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of -0.86, suggesting that its share price is 186% less volatile than the S&P 500.

Insider & Institutional Ownership

0.8% of Outlook Therapeutics shares are owned by institutional investors. 11.5% of Outlook Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ablynx Company Profile

Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.

Receive News & Ratings for Ablynx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ablynx and related companies with MarketBeat.com's FREE daily email newsletter.